Eloxx Pharmaceuticals Inc
ELOX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.22M
Close$
$0.31
79.7% downside
Current Fair Value
79.7% downsideOvervalued by 79.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.22 Million |
|---|---|
| Enterprise Value | $-5,141,804.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.49 |
| Beta | -24.6 |
| Outstanding Shares | 48,210,071 |
Return
| Return on Equity | 236.25% |
|---|---|
| Return on Assets | -210.71% |
| Return on Invested Capital | 224.78% |
Valuation & Multiples
| P/E Ratio | -0.76 |
|---|---|
| PEG | -16.9 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.3 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-5.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eloxx Pharmaceuticals Inc
CEO: Robert Ward